The impact of ethnicity on response to antihypertensive therapy

American Journal of Medicine

Volumn 101, Issue 3 A, 1996, Pages 22S-32S

  Jamerson, Kenneth ^a   DeQuattro, Vincent ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; IMIDAPRIL; QUINAPRIL; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; CORONARY RISK; COUGHING; DIABETES MELLITUS; DRUG EFFICACY; HEALTH CARE DELIVERY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MEDICAL DECISION MAKING; MINORITY GROUP; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; AMERICAN INDIAN; ASIAN AMERICAN; ETHNIC GROUP; ETHNOLOGY; HISPANIC; NEGRO;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIHYPERTENSIVE AGENTS; ASIAN AMERICANS; ETHNIC GROUPS; HEALTH SERVICES ACCESSIBILITY; HISPANIC AMERICANS; HUMANS; HYPERTENSION; INDIANS, NORTH AMERICAN; UNITED STATES;

EID: 0030607038     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00265-3     Document Type: Review

References (107)

1. Adams JM. Some racial differences in blood pressure and morbidity in groups of white and colored workmen. Am J Med Sci. 1932;184:342.
2. Hypertension Detection and Follow-up Program Cooperative Group. Race, education and prevalence of hypertension. Am J Epidemiol. 1977;106:351-361.
3. Ooi WL, Budner NS, Cohen H, Madhavan S, Alderman MH. Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension. 1989;14:227-234.
4. Harburg E, Erfurt JC, Hauenstein LS, Chape C, Schull WJ, Schork MA. Socioecological stress, suppressed hostility, skin color, and black-white male blood pressure: Detroit. Psychosom Med. 1973;35:276-296.
5. Klag MJ, Whelton PK, Coresh J, Grim CE, Kuller LH. The association of skin color with blood pressure in U.S. blacks with low socioeconomic status. JAMA. 1991;265:599-602.
6. Spielberger CD, Johnson EH, Russell SF, Crane RJ, Jacobs GA, Worden TJ. The experience and expression of anger: construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, eds. Anger and Hostility in Cardiovascular and Behavioral Disorders. Washington: Hemisphere, 1985:5-30.
7. Anderson NB, Myers HF, Pickering T, Jackson JS. Hypertension in blacks: psychosocial and biological perspectives. J Hypertens. 1989;7:161-172.
8. Jenkins DC, Zyzanski SJ, Rosenman RH. Jenkins Activity Survey. Psychological Corporation, 1979.
9. James SA, Hartnett SA, Kalsbeek WD. John Henryism and blood pressure differences among black men. J Behav Med. 1983;6:259-278.
10. U.S. Department of Health and Human Services. Report of the Secretary's Task Force on Black and Minority Health: Vol. VI: Cardiovascular and Cerebrovascular Disease, Part 2. Washington, DC: U.S. Government Printing Office, 1985:303-316.
11. Gillum RF. The epidemiology of coronary heart disease in blacks. J Natl Med Assoc. 1985;77:281-284.
12. Roberts J, Rowland M. Hypertension in adults 25-74 years of age, United States, 1971-1975, in Vital and Health Statistics, Series 11, No. 221. Hyattsville, MD, U.S. Department of Health and Human Services, 1981:81-1671.
13. U.S. Bureau of the Census. Current Population Reports, Series P-60, No. 176-RD. 1991.
14. Statistical Abstracts of the U.S., annual, 1991.
15. National Center for Health Statistics. Health, United States, 1988. DHHS Pub. No. (PHS) 89-1232. Washington, DC, Public Health Service, U.S. Government Printing Office, 1989.
16. Sempos C, Cooper R, Kovar MG, McMillen M. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health. 1988;78:1422-1427. (Published erratum appears in Am J Public Health. 1988;79:1422.)
17. McCord C, Freeman HP. Excess mortality in Harlem. N Engl J Med. 1990;322:173-177.
18. U.S. Renal Data System. USRDS 1989 Annual Report. Bethesda, MD, National Institutes of Health, NIDDK, 1989.
19. Mroczek WJ, Davidov M, Gavrilovich L, Finnerty FA Jr. The value of aggressive therapy in the hypertensive patient with azotemia. Circulation. 1969;40:893-904.
20. Mitchell HC, Graham RM, Pettinger WA. Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. Ann Intern Med. 1980;93:676-681.
21. Magee JH, Unger AM, Richardson DW. Changes in renal function associated with drug or placebo therapy of human hypertension. Am J Med. 1964;36:795-804.
22. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:684-688.
23. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
24. Lee DK, Marantz PR, Devereux RB, Alderman MH. Left ventricular hypertrophy and adverse cardiovascular outcome in black and white hypertensives. (Abstr.) Am J Hypertens. 1991;4:19A.
25. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry in morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
26. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105-112.
27. Beaglehole R, Tyroler HA, Cassel JC, Deubner DC, Bartel AG, Hames CG. An epidemiological study of left ventricular hypertrophy in the biracial population of Evans County, Georgia. J Chronic Dis. 1975;28:549-559.
28. Rautaharju PM, LaCroix AZ, Savage DD, Haynes SG, Madans JH, Wolf HK, Hadden W, Keller J, Cornoni-Huntley J. Electrocardiographic estimate of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the epidemiologic follow-up study of the First National Health and Nutrition Examination Survey. Am J Cardiol. 1988;62:59-66.
29. Bartel A, Heyden S, Tyroler HA, Tabesh E, Cassel JC, Hames CG. Electrocardiographic predictors of coronary heart disease. Arch Intern Med. 1971;128:939-937.
30. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990;81:528-536.
31. Fumo MT, Teeger S, Lang RM, Bednarz J, Sareli P, Murphy MB. Diurnal blood pressure variation and cardiac mass in American blacks and whites and South African blacks. Am J Hypertens. 1992;5:111-116.
32. Harshfield GA, Hwang C, Grim CE. Circadian variation of blood pressure in blacks: influence of age, gender and activity. J Hum Hypertens. 1990;4:43-47.
33. Johnson EH, Nazzaro P, Gilbert DC, Weder A, Jamerson K. Similarities in cardiovascular reactivity to behavioral stressors in African-American and white males. Ethn Dis. 1992;2:232-245.
34. Keys IR, Saunders E, Tesch D. 24 hour diurnal variation of blood pressure in blacks. Presented at Seventh International Interdisciplinary Conference on Hypertension in Blacks, Atlanta, GA. 1992. Unpublished.
35. Lee DK, Marantz PR, Devereux RB, Kligfield P, Alderman MH. Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences in prevalence. JAMA. 1992;267:3294-3299.
36. Burt VL, Whelton P, Rocella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Study. Hypertension. 1995;25:305-313.
37. Francis CK. Hypertension, cardiac disease, and compliance in minority patients. Am J Med. 1991;91(suppl 1A):29S-36S.
38. Sorlie PD, Backlund E, Johnson NJ, Rogot E. Mortality by Hispanic status in the United States. JAMA. 1993;270:2464-2468.
39. Winkleby MA, Fortmann SP, Rockhill B. Health-related risk factors in a sample of Hispanics and whites matched on sociodemographic characteristics. The Stanford Five-City Project. Am J Epidemiol. 1993;137:1365-1375.
40. Golding JM, Burnam MA. Immigration, stress, and depressive symptoms in a Mexican-American community. J Nerv Ment Dis. 1990;178:161-171.
41. McMurry MP, Cerqueira MT, Connor SL, Connor WE. Changes in lipid and lipoprotein levels and body weight in Tarahumara Indians after consumption of an affluent diet. N Eng J Med. 1991;325:1704-1708.
42. Haffner SM. Prevalence of hypertension in Hispanics in San Antonio and Mexico City. (Abstr.) Am J Hypertens. 1996;9:187A.
43. Hispanic health in the United States. Council on Scientific Affairs. JAMA. 1991;265:248-252.
44. Barrios E, Iler E, Mulloy K, Goldstein J, Chalfin D, Munoz E. Hypertension in the Hispanic and black population in New York City. J Natl Med Assoc. 1987;79:749-752.
45. Caralis PV. Hypertension in the Hispanic-American population. Am J Med. 1990;88:9S-16S.
46. Ramirez EA. Cardiovascular health in Puerto Ricans compared to other population groups in the United States. Bol Asoc Med PR. 1994;86:28-36.
47. Maldonado-Martinez M. Hypertension in Hispanics. Comments on a major disease in a mix of ethnic groups. Am J Hypertens. 1995;8:120S-123S.
48. Laffer CL, Elijovich F. Suboptimal outcome of management of metabolic cardiovascular risk factors in Hispanic patients with essential hypertension. Hypertension. 1995;26:1079-1084.
49. Li D, DeQuattro V, Hsueh W, Xiang A. Neurogenic factors, insulin and salt, on cardiovascular hypertrophy of hypertensives and their offspring. (Abstr.) Am J Hypertens. 1996;9:124A.
50. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
51. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
52. Bennett PH, Stern MP. Workshop VII - patient population and genetics: role in genetics. Am J Med. 1991;90(suppl):76S-79S.
53. Haffner SM, Mitchell BD, Pugh JA, Stern MP, Kozlowski MK, Hazuda HP, Patterson JK, Klein R. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care. 1989;12:530-536.
54. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med. 1995;333:343-347.
55. Saad M, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324:733-739.
56. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993;329:1988-1992.
57. Rosenthal M, McMahan CA, Stern MP, Eifler CW, Haffner SM, Hazuda HP, Franco LJ. Evidence of bimodality of two hour glucose concentrations in Mexican Americans: results from the San Antonio Heart Study. J Chron Dis. 1985;38:5-16.
58. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among Naurans. Prediction of deterioration in glucose tolerance over 6 years. Diabetes 1987;36:179-186.
59. Bergstrom RW, Newell-Morris LL, Leonetti DL, et al. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes. 1990;39:104-111.
60. Klatsky AL, Armstrong MA. Cardiovascular risk factors among Asian Americans living in Northern California. Am J Public Health. 1991;81:1423-1428.
61. Hohn AR, Dwyer KM, Dwyer JH. Blood pressure in youth from four ethnic groups: the Pasadena Prevention Project. J Pediatr. 1994;125:368-373.
62. Higashimori K, Zhao Y, Higaki J, et al. Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. Biochem Biophys Res Commun. 1993;191:399.
63. Nakai K, Itoh C, Miura Y, et al. Deletion polymorphism of angiotensin I converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994;90:2199-2202.
64. Duru K, Farrow S, Wang J, Lockette W, Kurtz T. Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension. Am J Hypertens. 1994;7:759-762.
65. Winklestein W, Kagan A, Kato H, et al. Epidemiologic studies of coronary disease and stroke in Japanese men living in Japan, Hawaii, and California: blood pressure distributions. Am J Epidemiol. 1975;102:502-513.
66. Peto R, Chen Z, Boreham J. Tobacco: the growing epidemic in China. JAMA. 1996;275:1683-1684.
67. Moore DJ, Williams JD, Quails WJ. Target marketing of tobacco and alcohol-related products to ethnic minority groups in the United States. Ethnicity Dis. 1966;6:83-98.
68. Schooler C, Basil MD. Alcohol and cigarette advertising on billboards: targeting with social cues. Paper presented at International Communication Association Conference, Dublin, Ireland, May 15, 1989.
69. Humphreys GS, Delvin DG. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968;2:601-603.
70. Chrysant SG, Danisa K, Kem DC, Dillard BL, Smith WJ, Frohlich ED. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension. 1979;1:136-141.
71. Zing W, Ferguson RK, Vlasses PH. Calcium antagonists in elderly and black hypertensive patients. Therapeutic controversies. Arch Intern Med. 1991;151:2154-2162.
72. Cook CA. Pathophysiologic and pharmacotherapy considerations in the management of the black hypertensive patient. Am Heart J. 1988;116:288.
73. Hall WD. Pathophysiology of hypertension in blacks. Am J Hypertens. 1990;3:366S-371S.
74. Weir MR. Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med. 1991;90(suppl):3S-14S.
75. Buhler FR. Antihypertensive treatment according to age, plasma renin and race. Drugs. 1988;35:495-503.
76. Luke RG. Can renal failure due to hypertension be prevented? Hypertension. 1991;18(3 suppl):I139-I142.
77. Tyroler HA. Socioeconomic status in the epidemiology and treatment of hypertension. Hypertension. 1989;13(5 suppl):I94-I97.
78. Ferdinand KC. New Joint National Committee recommendations as they affect black hypertensive patients. J Natl Med Assoc. 1989;81(suppl):31-40.
79. Hypertension-in black and white (editorial). Lancet. 1992;339:28-29.
80. Weinberger MH. Racial differences in antihypertensive therapy: evidence and implications. Cardiovasc Drugs Ther. 1990;4(suppl 2):379-382.
81. Batey DM, Nicolich MJ, Lasser VI, Jeffrey SS, Lasser NL. Prazosin versus hydrochlorothiazide as initial antihypertensive therapy in black versus white patients. Am J Med. 1989;86:74-78.
82. Townsend RR, DiPette DJ, Goodman R, Blumfield D, Cronin R, Gradman A, Katz LA, McCarthy EP, Sopko G. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther. 1990;48:665-675.
83. Kosoglou T, Cressman MD, Vlasses PH, Rocci ML Jr, Gabos C, Ferguson RK. Antihypertensive response to ketanserin: influence of race and weight. J Clin Pharmacol. 1988;28:1017-1022.
84. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Int. Med. 1990;15A:102-113.
85. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
86. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 191;265:3255-3264.
87. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
88. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992;304:405-412.
89. Gurwitz JH, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med. 1992;118:273-278.
90. Elliott WJ. Glucose and cholesterol elevations during thiazide therapy: intention-to-treat versus actual on-therapy experience. Am J Med. 1995;99:261.
91. Grimm RH, Flack JM, Grandits GA. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA. 1996;275:1549-1556.
92. Walker WG, Hermann JA, Anderson JA. Randomized doubly blinded trial of enalapril (E) vs hydrochlorothiazide (H) on glomerular filtration rate (GFR) in diabetic nephropathy: early vs late results. (Abstr.) Hypertension. 1993;22:410.
93. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
94. Lewis EJ, Hunsicker LG, Bain RP, et al. The effects of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
95. Parra-Carrillo JZ, Diaz-Barreiro LC, Olvera S. Curr Ther Res. 1992;51:185-195.
96. Weber M, Dzau V, Julius S. ASCEND (Accupril Study of Clinical, Economic, and Dose Titration End Points): effect of up titration and compliance on response rate. (Abstr.) Am J Hypertens. 1996;9:72A.
97. Alderman MH, Madhavan S, Cohen H. Antihypertensive drug therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year. Am J Hypertens. 1996;9:413-418.
98. Silva H. Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin, London, England, 1990. (Poster presentation.)
99. Lee D, Lu Z, DeQuattro V. Neural mechanisms in primary hypertension. Efficacy of alpha-blockade with doxazosin during stress. Am J Hypertens. 1996;9:47-53.
100. Pasic J, Hui KK. Do Asian hypertensive patients require alteration in hypertension management? A physician survey. (Abstr.) Am J Hypertens. 1996;9:172A.
101. Pasic J, Hui KK. Interaction of pharmacological response to antihypertensive therapy and clinical outcome in Asian Americans. (Abstr.) Am J Hypertens. 1995;8:139A.
102. Tomlinson B, Critchley J, Sanderson JE, et al. Thiazide diuretic dose-response in Chinese hypertensives. (Abstr.) Tenth International Interdisciplinary Conference on Hypertension in Blacks, St. Thomas, Virgin Islands, June 24-27, 1995.
103. Jones DW, Kim D, Sands CD, et al. ACE inhibitor associated cough in Asians. (Abstr.) Tenth International Interdisciplinary Conference on Hypertension in Blacks, St. Thomas, Virgin Islands, June 24-27, 1995.
104. Saruta T, Omae T, Kuramochi M, Iimura O, Yoshinaga K, Abe K, Ishii M, Watanabe M, Takeda T, Ito K, Kokubu T, Fujishima M, Arakawa K, Nakajima M. Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens. 1995;13(suppl 3):S23-S30.
105. Taylor SH. Amlodipine treatment of hypertension in general practice: an Asian, multicenter perspective. XI Asian-Pacific Congress of Cardiology, Bali, Indonesia, 1995.
106. Kloner RA, Sowers JR, DiBona GF, et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol. 1996;77:713-722.
107. Parmley WW. A delayed answer to the calcium channel blocker question. J Am Coll Cardiol. 1996;27:510-511.